Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Phase 2
50
about 2.6 years
18–70
1 site in MD
What this study is about
Researchers are testing a treatment called (2R,6R)-hydroxynorketamine (HNK) to see if it can help people with depression who haven't responded well to other treatments. The trial will last for 967 days and involve giving HNK or a placebo through an IV infusion over several weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from baseline on Montgomery-Asberg Depression Rating Scale total scores
Secondary: Change from baseline on Montgomery-Asberg Depression Rating Scale total scores, Change from baseline on item 10 (suicidality) of the Montgomery-Asberg Depression Rating Scale and total score on the Columbia Suicide Severity Rating Scale and the Scale for Suicide Ideation., Change from baseline on the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Positive and Negative Affect Schedule, Snaith-Hamilton Pleasure Scale, Temporal Experience of Pleasure Scale, and cognitive tasks., Incidence of AEs and total scores using the Clinician Administered Dissociative States Scale, Young Mania Rating Scale, Brief Psychiatric Rating Scale, vital signs, changes in clinical laboratory evaluations, and electrocardiograms., Pain thresholds and tolerance during quantitative sensory testing while undergoing fMRI., Pain thresholds and tolerance during quantitative sensory testing., Proportion of participants achieving response (defined as a >/=50% reduction from baseline in Montgomery-Asberg Depression Rating Scale total score), Proportion of participants in remission (defined as Montgomery-Asberg Depression Rating Scale total score =10)
Psychiatry / Mental Health